Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Cue Biopharma ( (CUE) ) has shared an announcement.
At its April 13, 2026 annual meeting, Cue Biopharma stockholders elected six directors, including Pasha Sarraf and Pamela Garzone, to serve until the next annual meeting, while noting that all votes cast for former CEO Usman Azam, who resigned on March 26, 2026, were disregarded. Shareholders also ratified RSM US LLP as independent auditor for the 2026 fiscal year and approved, on a non-binding basis, the compensation of the company’s named executive officers, reinforcing the current leadership and governance framework.
Investors further approved an amendment authorizing the board to implement a reverse stock split in a range of 1-for-30 to 1-for-50 at its discretion, providing the company with flexibility to manage its share price and capital structure. These outcomes collectively position Cue Biopharma to adjust its equity profile while maintaining continuity in board oversight and executive pay practices, with potential implications for trading dynamics and shareholder value.
The most recent analyst rating on (CUE) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Cue Biopharma stock, see the CUE Stock Forecast page.
Spark’s Take on CUE Stock
According to Spark, TipRanks’ AI Analyst, CUE is a Neutral.
The score is held back primarily by weak financial performance—persistent losses and negative free cash flow despite improved revenue and reduced debt. Offsetting factors include strong technical momentum (though currently overbought) and a positive corporate milestone with an expected $7.5M payment that supports liquidity.
To see Spark’s full report on CUE stock, click here.
More about Cue Biopharma
Cue Biopharma, Inc. is a biotechnology company focused on developing therapeutics, operating in the biopharmaceutical industry. The company’s stock is publicly held, and it maintains a typical U.S. corporate governance structure with a board of directors and named executive officers subject to stockholder oversight.
Average Trading Volume: 7,381,465
Technical Sentiment Signal: Sell
Current Market Cap: $49.02M
See more data about CUE stock on TipRanks’ Stock Analysis page.